Pular para o conteúdo principal
Ranking Invest

CPRX - Catalyst Pharmaceuticals, Inc.

Segmento: HealthcareCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Análise Ranking Invest

Valuation estimado
$ 1.63 Bi
IVR
0.42A companhia vale 0,42 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.14O valuation alternativo equivale a 14% do valor de mercado da companhia.
MLL
0.14O lucro líquido dos controladores em 16 trimestres equivale a 14% do valor de mercado.
Último Balanço Atualizado: 1T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.01 Bi

Dívida Líquida

-$ 755.86 Mi

L4T

$ 221.32 Mi

MM4T

37.08%

Indicadores Básicos

ROE

21.85%

Índices de Previsibilidade

Receita Líquida

D0.08

Lucro

A0.08

Margem

A0.10

Índices de Tendência

Receita Líquida

A11.46

Lucro

A11.64

Margem

D-0.53

Índices de Endividamento

DIV/PAT

-0.75

DIV/L4T

-3.42

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.